There is convincing epidemiological evi dence indicating that the serum levels of high density lipoprotein (HDL) cholesterol are inversely related to the risk of vascular events. Similarly, intervention trials, involving healthy populations and patients with coro nary heart disease (CHD), have shown that raising the serum levels of HDL is associat ed with a significant decrease in the risk of vascular events. It follows that serum HDL levels must be considered when assessing risk and setting therapeutic goals. Some of the currently available national treatment guide lines reflect this view The present review considers the place of serum HDL measure ment in the prevention of vascular events.
Assmann G. and Shulte H. (1992). Relation of high density lipoprotein cholesterol and triglycerides to the incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol; 70, 733-737
2.
Boden W.E. and Pearson T.A. (2000). Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am J Cardiol ; 85, 645-650
3.
Crouse Iii J R , Frohlich J., Ose L., Mer-Curi M. and Tobert J.A. (1999). Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol; 83, 1476-1477
4.
De Backer G., De Bacquer D. and Kor-Nitzer M. (1998). Epidemiological aspects of high density lipoprotein cholesterol. Atherosclerosis; 137(S), 1-6
5.
Dhawan J., Bray C.L., Warburton R., Ghambhir D.S. and Morris J. (1994). Insulin resistance, high prevalence of diabetes, and cardiovascular risk in immigrant Asians. Genetic or environmental effect?Br Heart J; 72, 413-421
6.
Ganotakis E.S. and Mikhailidis D.P. (1996). Bezafibrate: treating hyperlipidaemias as well as other cardiovascular risk factors. Today's Therap Trends; 13, 231-249
7.
Gotto A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., et al (2000). Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation ; 101, 477-484
8.
Guerin M.Lassel T.S., Le Goff W., Farnier M. and Chapman M.J. (2000). Action of atorvastatin in combined hyperlipidemia . Arterioscler Thromb Vasc Biol; 20, 189-197
9.
Kastelein J.Q.Stein E.A., Davidson M.A., Crouse J.R., Ose L., Liu M., et al (2000). Simvastatin increases HDL-C and apolipoprotein A-1 levels significantly more than atorvastatin. J Am Coll Cardiol; 33(SA); 315a (abstract 1009-1173)
10.
Lipid (The Long-Term Intervention With Pravastatin In Ischemic Disease) Study Group (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med; 339, 1349-1357
11.
Mckeigue P.M., Shah B. and Marmot M.G. (1991). Relationship of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet; 337, 382-386
12.
Mikhailidis D.P. and Wierzbicki A.S. (2000). HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin; 16, 139-146
13.
Milionis H.J., Elisaf M.S. and Mikhailidis D.P. (2000). Treatment of dyslipidaemias in patients with established vascular disease: a review of the fibrates . Curr Med Res Opin; 16, 21-32
14.
Nair D.R. and Mikhailidis D.P. (2000). Ischaemic heart disease in South Asians - the ethnic difference. J Indian Med Assoc; 1, 18-22
15.
Paolisso G., Barbagallo M., Petrella G., Ragno E., Barbeiri M., Giordano M., et al (2000). Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis ; 150, 121-127
16.
Papadakis J.A., Ganotakis E.S. and Mikhailidis D.P. (2000). Beneficial effect of moderate alcohol consumption on vascular disease: myth or reality?J Roy Soc Health; 120, 11-15
17.
Papadakis J.A.Ganotakis E.S., Jagroop I.A., Winder A.F. and Mikhailidis D.P. (1999). Statin + fibrate combination therapy: fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol; 40, 265-271
18.
Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., et alfor THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP (1998). Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation; 97, 1453-1460
19.
Riegger G., Ablethauser C., Ludwig M., Schwandt P., Widimsky J., Weidinger G., et al (1999). The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis; 144, 263-270
20.
Rifkind B.M. (1990). High-densiy lipoprotein cholesterol and coronary artery disease: survey of the evidence. Am J Cardiol; 66, 3A-6A
21.
Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam MB, et al (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol . N Engl J Med; 341, 410-418
22.
Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al for The Cholesterol And Recurrent Events Trial Investigators (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med; 335,1001-1009
23.
Scandinavian Simvastatin Survival Study Group ( 1994). Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study . Lancet;344,1383-1389
24.
Shepherd J. (1995). Fibrates and statins in the treatment of hyperhpidaemia: an appraisal of their efficacy and safety. Eur Heart J ; 16, 5-13
25.
Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., et al for The West Of Scotland Coronary Prevention Study Group (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia . N Engl J Med; 333, 1301-1307
26.
Wallis E.J., Ramsay L.E., Ul Haq I., Ghahramani P., Jackson P.R., Rowland-Yeo K., et al (2000). Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ ; 320, 671-676
27.
Wierzbicki A.S., Lumb P.J., Chik G. and Crook M.A. (1999). Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int J Clin Pract; 53, 609-611
28.
Wierzbicki A.S., Crook M.A., Nair D., Mikhailidis D.P. and Winder A.F. (2000). More on statins and fibrinogen. Atherosclerosis; 148, 204
29.
Wood D., Durrington P., Poulter N., Mcinnes G., Rees A. and Wray R. on behalf of The British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society And British Diabetic Association (1998). Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart; 80(S2),1-29
